The Medical Letter® On Drugs and Therapeutics

Published by The Medical Letter, Inc. • 1000 Main Street, New Rochelle, NY 10801 • A Nonprofit Publication

Important Copyright Message

The Medical Letter® publications are protected by US and international copyright laws. Forwarding, copying or any distribution of this material is prohibited.

Sharing a password with a non-subscriber or otherwise making the contents of this site available to third parties is strictly prohibited.

By accessing and reading the attached content I agree to comply with US and international copyright laws and these terms and conditions of The Medical Letter, Inc.

For further information click: Subscriptions, Site Licenses, Reprints or call customer service at: 800-211-2769

The Medical Letter publications are protected by US and international copyright laws. Forwarding, copying or any other distribution of this material is strictly prohibited.

For further information call: 800-211-2769

The Medical Letter®

On Drugs and Therapeutics

Published by The Medical Letter, Inc. • 1000 Main Street, New Rochelle, NY 10801 • A Nonprofit Publication

Volume 51 (Issue 1327/1328) December 14/28, 2009 www.medicalletter.org

Happy New Year

The Medical Letter publishes 26 issues per year. This is the last issue of 2009. The first issue of 2010 will be dated January 11th.

Screening Mammography for Women 40-49 Years Old

Conflicting recommendations on when to screen for breast cancer are problematic for healthcare providers. The recent recommendation by the US Preventive Services Task Force (USPSTF) against routine screening mammography for women 40-49 years old¹ conflicts with recommendations made by other organizations such as the American Cancer Society and earlier recommendations made by the USPSTF in 2002.

THE EVIDENCE — All of these recommendations are based on meta-analyses of pooled data from clinical studies that vary in quality. Since 2002, one new study has been published and additional data from one old study has been reported.

The new study (the Age trial) was a randomized trial in the UK in which 53,884 women 39-41 years old were invited to annual screening mammography until age 48, and 106,956 women who were not invited served as the control group; both groups were followed for a mean of 10.7 years. Adherence to the assignments was not well documented; no more than 70% of women randomized to screening were actually screened each year. The women assigned to screening had a nonsignificant 17% lower incidence of breast cancer mortality. Women who accepted their first invitation to screening had a nonsignificant decrease of 24% in breast cancer mortality.2 The Age study mainly used single-view mammography, which is widely considered less reliable than 2-view or digital mammography.

The new data from the old trial indicated that women 39-49 years old randomly assigned to screening with mammography every 18 months and followed for 13 years

had a nonsignificant 31% lower incidence of breast cancer mortality.³

Based on these studies and earlier ones like them, the USPSTF calculated that an invitation to screening mammography significantly reduced breast cancer mortality by 15% in women 39-49 years old. A total of 1904 women 39-49 years old would need to be invited to be screened to prevent one woman from dying of breast cancer. This number would be 1339 in women 50-59, and 377 in women 60-69 years old.4

PROBLEMS IN SCREENING — Younger women have a lower overall incidence of disease and have denser breasts that make tumors more difficult to detect. False-positive results occur in 9.8% of women 40-49 per screening round and in 8.7% of those 50-59 years old. Mammograms are followed by biopsies in 0.93% of women 40-49 and in 1.08% of those 50-59 years old.⁴ Other harms of screening younger women include more radiation exposure, unnecessary surgery, pain, anxiety and expense.

SCREENING INTERVALS — Studies that have shown a mortality benefit from screening mammography have used screening intervals of 12-33 months. Statistical models indicate that screening biennially provides 81% of the benefit (range 67-99%) of annual screening, with half the number of false-positive results and unnecessary biopsies.⁵ Based on their calculations of benefits and harms, the USPSTF has recommended biennial screening for women 50-74 years old.

CONCLUSION — Not offering routine mammography to women 40-49 years old would save many women from radiation exposure, unnecessary surgery, pain, anxiety and expense, at the cost of some lives. □

- USPSTF. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009; 151:716.
- SM Moss et al. Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: a randomised controlled trial. Lancet 2006; 368:2053.
- N Bjurstam et al. The Gothenburg breast screening trial. Cancer 2003; 97:2387.

- HD Nelson et al. Screening for breast cancer: An update for the U.S. Preventive Services Task Force. Ann Intern Med 2009; 151:727.
- JS Mandelblatt et al. Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med 2009; 151:738.

The Medical Letter®

On Drugs and Therapeutics

EDITOR IN CHIEF: Mark Abramowicz, M.D. EXECUTIVE EDITOR: Gianna Zuccotti, M.D., M.P.H., F.A.C.P., Harvard Medical School

EDITOR: Jean-Marie Pflomm, Pharm.D.

ASSISTANT EDITORS, DRUG INFORMATION: Susan M. Daron, Pharm.D., Blaine M. Houst, Pharm.D., Corinne E. Zanone, Pharm.D.

ADVISORY BOARD:

Jules Hirsch, M.D., Rockefeller University

Gerald L. Mandell, M.D., University of Virginia School of Medicine Dan M. Roden, M.D., Vanderbilt University School of Medicine

CONTRIBUTING EDITORS:

Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School

Eric J. Epstein, M.D., Albert Einstein College of Medicine David N. Juurlink, BPhm, M.D., Ph.D., Sunnybrook Health Sciences Centre

Richard B. Kim, M.D., University of Western Ontario

Hans Meinertz, M.D., University Hospital, Copenhager Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine

F. Estelle R. Simons, M.D., University of Manitoba Jordan W. Smoller. M.D., Sc.D., Harvard Medical School

Neal H. Steigbigel, M.D., New York University School of Medicine

SENIOR ASSOCIATE EDITORS: Donna Goodstein, Amy Faucard

ASSOCIATE EDITOR: Cynthia Macapagal Covey

EDITORIAL FELLOW: Vincent Teo, B.Sc. Phm, Sunnybrook Health Sciences Centre

MANAGING EDITOR: Susie Wong ASSISTANT MANAGING EDITOR: Liz Donohue PRODUCTION COORDINATOR: Cheryl Brown

EXECUTIVE DIRECTOR OF SALES: Gene Carbona FULFILLMENT & SYSTEMS MANAGER: Cristine Romatowski DIRECTOR OF MARKETING COMMUNICATIONS: Joanne F. Valentino VICE PRESIDENT AND PUBLISHER: Yosef Wissner-Levy

> Founded in 1959 by Arthur Kallet and Harold Aaron, M.D.

Copyright and Disclaimer: The Medical Letter is an independent nonprofit organization that provides health care professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter is supported solely by subscription fees and accepts no advertising, grants or dona-

No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The editors do not warrant that all the material in this publication is accurate and complete in every respect. The editors shall not be held responsible for any damage resulting from any error, inaccuracy or omission.

Subscription Services

Mailing Address:

The Medical Letter Inc. 1000 Main Street

New Rochelle, NY 10801-7537

Customer Service:

Call: 800-211-2769 or 914-235-0500

Fax: 914-632-1733

Web Site: www.medicalletter.org E-mail: custserv@medicalletter.org

Permissions:

To reproduce any portion of this issue, please e-mail your request to: permissions@medicalletter.org

Subscriptions (US):

1 year - \$98; 2 years - \$167; 3 years - \$235. \$49.00 per year for students, interns, residents and fellows in the US and Canada. CME: \$70 for 26 credits.

E-mail site license inquiries to:

info@medicalletter.org or call 800-211-2769 x315. Special fees for bulk subscriptions. Special classroom rates are available. Back issues are \$12 each. Major credit cards accepted.

Copyright 2009. ISSN 1523-2859